title: Oral topical cidofovir: novel route of drug delivery in a severely immunosuppressed patient with refractory multidrug-resistant herpes simplex virus infection.
abstract: We present a case of serious treatment-refractory acyclovir- and foscarnet-resistant herpes simplex virus (HSV) type-1 orolingual infection that responded to oral cidofovir rinses after failure of acyclovir and foscarnet therapy. The use of 3% cidofovir in a saline rinse for refractory mucosal HSV infection appears promising but needs prospective evaluation.
authors.affiliation: Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
authors.forename: C R
authors.initials: CR
authors.lastname: Sims
authors.forename: K
authors.initials: K
authors.lastname: Thompson
authors.forename: R F
authors.initials: RF
authors.lastname: Chemaly
authors.forename: E J
authors.initials: EJ
authors.lastname: Shpall
authors.forename: R E
authors.initials: RE
authors.lastname: Champlin
authors.forename: A
authors.initials: A
authors.lastname: Safdar
mesh_terms: D000287:Administration, Topical; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000077404:Cidofovir; D003596:Cytosine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D024921:Drug Resistance, Multiple, Viral; D005260:Female; D018259:Herpesvirus 1, Human / Q000302:isolation & purification*; D006801:Humans; D016867:Immunocompromised Host; D008875:Middle Aged; D009067:Mouthwashes; D063065:Organophosphonates / Q000008:administration & dosage* / Q000009:adverse effects; D033581:Stem Cell Transplantation; D013283:Stomatitis, Herpetic / Q000188:drug therapy* / Q000276:immunology* / Q000821:virology
chemical_list: D000998:Antiviral Agents; D009067:Mouthwashes; D063065:Organophosphonates; D003596:Cytosine; D000077404:Cidofovir